Abstract: The invention provides a method for evaluating deep-buried tunnel blasting parameters, and belongs to the technical field of mine engineering. The method comprises: setting multiple diverse blasting schemes; selecting a plurality of test sections with the same geological characteristics, the number of the test sections corresponding to the number of the blasting schemes; blasting the test sections using the blasting schemes, and obtaining diversified monitoring data of each test section; and comparing the diversified monitoring data to select the optimal blasting schemes for the test sections. According to the method for evaluating the deep-buried tunnel blasting parameters, by implementing different blasting schemes in test sections with the same geological characteristics, diversified monitoring data of the test sections are obtained and compared to select the optimal blasting schemes for the test sections, so as to ensure the safety and quality of blasting excavation of deep-buried tunnels.

Abstract: Systems and methods for agent-based error resolution in private cloud application using reinforcement learning and chaos experiments are disclosed. In one embodiment, a method for training an agent computer program using reinforcement learning and chaos experiments may include: (1) causing, by an agent management computer program, a failure in a simulated environment that the agent computer program is deployed, wherein the agent computer program is configured to implement an action in response to the failure; (2) detecting, by the agent management computer program, an impact of the action in the simulated environment; and (3) rewarding, by the agent management computer program, the agent computer program in response to the impact of the action being a positive impact.

Abstract: Provided are a dezocine derivative represented by Formula I, or a tautomer, optical isomer, nitrogen oxide, solvate, pharmaceutically acceptable salt or prodrug thereof, as well as a pharmaceutical composition containing the same, preparations thereof, and medical use thereof, and the structure of Formula I is as below:

Abstract: Disclosed is a crystal form of dezocine. The X-ray powder diffraction (XRD) pattern thereof is determined using Cu/K-?1 and has diffraction peaks at the 2? value of 9.1±0.2 and 12.2±0.2, with the height % of these diffraction peaks greater than 20. Also disclosed are a preparation method for the crystal form, a pharmaceutical composition and use thereof. The crystal form of dezocine has good solubility, the preparation method has simple operations, good reproducibility, suitability for industrial production and the like.

Abstract: Disclosed is a crystal form of dezocine. The X-ray powder diffraction (XRD) pattern thereof is determined using Cu/K-?1 and has diffraction peaks at the 2? value of 9.1±0.2 and 12.2±0.2, with the height % of these diffraction peaks greater than 20. Also disclosed are a preparation method for the crystal form, a pharmaceutical composition and use thereof. The crystal form of dezocine has good solubility, the preparation method has simple operations, good reproducibility, suitability for industrial production and the like.